Last 80.00 GBp
Change Today 0.00 / 0.00%
Volume 16.7K
AGL On Other Exchanges
As of 11:30 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

angle plc (AGL) Snapshot

80.00 GBp
Previous Close
80.00 GBp
Day High
80.00 GBp
Day Low
80.00 GBp
52 Week High
01/16/14 - 103.00 GBp
52 Week Low
08/29/13 - 56.00 GBp
Market Cap
Average Volume 10 Days
-0.03 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for ANGLE PLC (AGL)

Related News

No related news articles were found.

angle plc (AGL) Related Businessweek News

No Related Businessweek News Found

angle plc (AGL) Details

ANGLE plc, a medical diagnostic company, provides cancer diagnostics and foetal health products, and technology consultancy services primarily in the United Kingdom. The company’s lead product includes Parsortix cell separation device, which captures very rare circulating tumor cells in cancer patient blood. It also offers EmbryoSure for selecting embryos likely to lead to a successful pregnancy; and develops therapeutic products for the treatment of multiple sclerosis (MS) and Alzheimer’s disease (AD). In addition, the company provides management services, such as specialist consulting; design and delivery of specialist business support programs; commercialization support; fund raising; horizon scanning, technology appraisals, and market validation services; recruitment, development, and coaching of senior management team; business planning and investment readiness support for commercial and public sector projects; and planning, design, and delivery of specialist infrastructure, including clusters, science parks, and business incubators. ANGLE plc was founded in 1994 and is based in Guildford, the United Kingdom.

29 Employees
Last Reported Date: 10/4/13
Founded in 1994

angle plc (AGL) Top Compensated Officers

Founder, Group Chief Executive, Member Execut...
Total Annual Compensation: 194.0K GBP
Finance Director, Company Secretary, Member o...
Total Annual Compensation: 87.0K GBP
Compensation as of Fiscal Year 2013.

angle plc (AGL) Key Developments

ANGLE Plc Presents at BioTrinity 2014 - European Biopartnering and Investment Conference, May-12-2014

ANGLE Plc Presents at BioTrinity 2014 - European Biopartnering and Investment Conference, May-12-2014 . Venue: London, United Kingdom.

ANGLE plc Announces Parsortix FDA Submission

ANGLE plc announced it has made a submission to the United States Food and Drug Administration for authorisation of its Parsortix cell separation system for sale as an in vitro diagnostic device in the United States. The submission has been made under the FDA's 510(k) programme, one of the regulatory pathways for medical devices in the United States. ANGLE anticipates that the Parsortix system will receive FDA clearance by the end of third quarter of 2014, although no guarantees can be made around the exact timing of authorisation. FDA regulatory clearance would allow sale of the Parsortix system to hospital pathology laboratories and other clinical customers in the United States for the harvesting and molecular analysis of large cells such as circulating tumour cells (CTCs) from patient blood. There are currently no systems for harvesting CTCs for molecular analysis with FDA clearance for use with patients in the United States. There is the prospect therefore that ANGLE's Parsortix system may be the first such system cleared by the FDA. This would give ANGLE a market lead in the United States as new CTC based treatments for personalised cancer care emerge into mainstream medical practice.

ANGLE Plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended October 31, 2013

ANGLE Plc announced unaudited consolidated earnings results for the six months ended 31 October 31, 2013. For the period, the company reported revenue of £414,000 against £467,000 a year ago. Operating loss was £556,000 against £373,000 a year ago. Loss before tax was £476,000 against £359,000 a year ago. Loss for the period was £476,000 against £359,000 a year ago, reflecting the planned increased level of investment in Parsortix and a fair value gain on the investment in Geomerics. Loss for the period attributable to owners of the parent company was £396,000 against £269,000 a year ago. Basic and diluted loss per share was £1.05 against £0.93 a year ago. Net used in operating activities was £747,000 against £665,000 a year ago. Purchase of property, plant and equipment was £84,000 against £71,000 a year ago. Purchase of intangible assets was £235,000 against £389,000 a year ago. Capitalized expenditure was £0.3 million against £0.6 million a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGL:LN 80.00 GBp 0.00

AGL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGL.
View Industry Companies

Industry Analysis


Industry Average

Valuation AGL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 24.9x
Price/Book 5.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 24.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANGLE PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at